Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability

Journal of Child Neurology

Volumn 22, Issue 5, 2007, Pages 574-579

  Chez, Michael G ^a,b   Burton, Quinn ^a   Dowling, Timothy ^a   Chang, Mina ^a   Khanna, Pavan ^a   Kramer, Christopher ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b NONE   (United States)

Author keywords

Autism treatment; Memantine; Pervasive developmental disorders

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONIDINE; DONEPEZIL; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; GUAIFENESIN; LITHIUM DERIVATIVE; MEMANTINE; METHYLPHENIDATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIZANIDINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; AUTISM; BEHAVIOR DISORDER; BLOOD CHEMISTRY; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LANGUAGE DISABILITY; LIVER EXAMINATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; SELF STIMULATION; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMANTINE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 34250731835     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073807302611     Document Type: Article

References (20)

1. Schieve LA, Rice C., Boyle C., et al. Parental report of diagnosed autism in children aged 4-17 years-United States, 2003-2004. MMWR. 2006; 55: 481-486.
2. Bauman ML, Kemper TL Histoanatomic observations of the brain in early infantile autism. Neurology. 1985; 35: 866-874.
3. Bauman ML, Kemper TL The Neurobiology of Autism. Baltimore: Johns Hopkins University Press; 1994.
4. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001; 158: 1058-1066.
5. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001; 57: 1618-1628.
6. Vargas DL, Nascimbene C., Krishman C., et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005; 57: 67-81.
7. Parsons CG, Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: A review of preclinical data. Neuropharmacology. 1999; 38: 735-767.
8. Namenda (memantine hydrochloride) [prescribing information]. St Louis, Mo: Forest Laboratories; 2005.
9. Chez MG, Buchanon T., Becker M., et al. Donezepil hydrochloride: A double-blind study in autistic children. J Pediatr Neurol. 2003; 1: 83-88.
10. Hardan AY, Handen BL A retrospective open trial of adjunctive donezepil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002; 12: 237-241.
11. Chez MG, Aimonovitch M., Buchanon T., et al. Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004; 19: 165-169.
12. Chez MG, Hung PC, Chin K., et al. Memantine experience in children and adolescents with autistic spectrum disorders [abstract]. Ann Neurol. 2004; 56 (suppl): 109.
13. Chez MG, Chin K., Memom S., Hung P. Memantine as add-on therapy in pediatric epilepsy patients: Effects on cognitive development and seizure frequency. Epilepsia. 2004; 45 (suppl):1.406.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
15. Guy W. Clinical Global Impression (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Publ. no. 76-338. Rockville, Md: US Department of Health, Education, and Welfare; 1976: 218-222.
16. Aman MG, Novotny S., Samango-Sprouse C., et al. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004; 9: 36-47.
17. Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004; 161: 2115-2117.
18. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001; 40: 658-665.
19. Hollander E., Phillips A., King BH, et al. Impact of recent findings on study design of future autism clinical trials. CNS Spectr. 2004; 9: 49-56.
20. Chez MG, Chang M., Krasne V., et al. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav. 2006; 8: 267-271.